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Abstract
Background: Gastro-esophageal reflux disease (GERD) is one of the most widespread gastrointestinal disorders. In addition, there
is increasing evidence that not all patients respond to its current remedies.
Objectives: The aim of this pilot study was to investigate the effect of “Satureja hortensis L.” on improving the symptoms of mild to
moderate GERD in adults.
Methods: In this double-blind, randomized, controlled, clinical trial, we evaluated the efficacy of “Satureja hortensis L.” compared
to placebo in the symptoms of GERD in fifty-eight adults with GERD who referred to Hazrat Rasool-e-Akram hospital in Tehran, Iran,
in 2015. In order to assess GERD symptoms, a standardized questionnaire of frequency scale (FSSG) was used before and after the
intervention.
Results: Regarding within-group changes, a significant decrease was observed in FSSG, dysmotility-like symptoms and acid reflux
related scores in both groups of the study after the intervention compared to baseline (P < 0.001). Regarding between-group anal-
ysis, no significant differences were observed between the two groups in terms of FSSG total scores (0.05 < P).
Conclusions: According to the results of the current study, Satureja hortensis L. with the dose of 500 mg three times per day failed to
improve the symptoms of GERD in adults compared to placebo. The significant reductions in the GERD scores in both groups seem
to be related to the lifestyle modification that was prescribed to both groups.
Keywords: Heartburn, GERD, Savory Plant, Saturejas, Herbal Medicine
1. Background
Gastro-esophageal reflux disease (GERD) is a condition
that occurs when contents of the stomach reflux into the
esophagus, leading to troublesome symptoms and/or mu-
cosal lesions in the distal esophagus (1). GERD is a com-
mon problem affecting nearly 20% of people in Iran and
so does in western countries, making it one of the most
widespread gastrointestinal disorders (2, 3). Most of the
people with reflux disease show mild symptoms and need
little, if any, medication. Few patients will require surgery;
and in the rest, control of symptoms needs continuing
acid-suppression therapy; the latter requires maintenance
of medical management (4, 5). Long-term usage of sup-
pressing gastric acid has lately been associated with a mul-
titude of side effects such as enteric infections, sustained
hyper-gastrinemia , impaired vitamin B, and iron absorp-
tion, acute interstitial nephritis, colon or gastric malignan-
cies, osteoporosis, myopathy, acute coronary syndromes,
and rebound acid hypersecretion (4, 6). In addition, there
is increasing evidence that not all patients respond satis-
factorily to this kind of remedy and about one-third of the
patients need additional intervention to manage symp-
toms (7). Besides conventional intervention, complemen-
tary and alternative medicine (CAM) has introduced many
approaches for this disorder (8). As well, new investiga-
tions have introduced various methods such as natural ap-
proaches, lifestyle modification, and herbal medicine for
the management of GERD symptoms (9-11).
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The traditional Persian medicine (TPM), which dates
back to thousands of years ago, consists of the assemblage
of whole knowledge applied in diagnosis, prevention, and
treatment of diseases in Iran from ancient times until now
(12-18). TPM has given more regard and importance to
the prevention of a disease rather than its treatment, so
“lifestyle modification” is the first approach to the man-
agement of the diseases. After modifying the lifestyle, the
use of simple remedies is the second approach to control-
ling diseases. Finally, if a disease does not improve through
simple treatment, the third line will be the administration
of compound medicines comprising two or more simple
medicines (19, 20).
Satureja hortensis L (Savory) is an edible vegetable that
Iranian people use as a flavor component in their diet. In
addition, in Iranian folk medicine, S. hortensis has been
used as a carminative and antispasmodic remedy for disor-
ders like mild to moderate GERD (21). Studies have shown
the effectiveness of S. hortensis as an anti-inflammatory fac-
tor in acute inflammation of the stomach and intestines, as
well as carminative, anti-diarrhea, pain relieving, antibac-
terial, antiviral, antifungal, and anti-oxidant medication
(22-24).
The aim of this study was to assess the efficacy of
“lifestyle modification” and “S. hortensis” in improving the
symptoms of GERD in a pilot open-label clinical trial.
2. Methods
2.1. Study Design
This study is a randomized, double-blind, placebo-
controlled clinical trial performed at Iran University of
Medical Sciences. In this trial, we evaluated the effect of
lifestyle modification” and “S. hortensis” on improving the
symptoms of GERD in a pilot open-label clinical trial. No
changes occurred to methods after trial commencement.
2.2. Sample Size Calculation
The sample size was calculated by considering a one-
sided significance level of 0.05 and 0.80 power based on
the comparison of means of FSSG to detect the mean differ-
ence of 6± 9 before and after the intervention, and a prob-
able 10% dropout rate totaling 29 patients in each group.
The sample size was calculated using the PASS 11 software.
2.3. Selection of Patients and Assessment Criteria
In this randomized pilot study, fifty-eight patients with
symptoms of GERD visited by gastroenterology special-
ist were gathered from Hazrat Rasool-e-Akram hospital in
Tehran, Iran (It is a governmental and referral hospital).
Written informed consent was obtained from patients be-
fore participating in this study. Patients aged 18 - 65 with
mild to moderate symptomatic GERD (discomfort enough
to interfere with ordinary activities such as sleep or work)
diagnosed by a gastroenterologist were included in the
study. The exclusion criteria consisted of occult blood
(OB) positive, risk of cancer, risk of peptic ulcer, pregnancy
and breastfeeding, any digestive disorder requiring new
protocols, abnormalities of laboratory tests (such as low
hemoglobin, high ESR, CRP positive, and so on), signif-
icant surgical or medical disorders, hospitalization, and
non-users of S. hortensis capsules for 2 weeks. A standard-
ized questionnaire of frequency scale for the symptoms
of GERD (FSSG) was filled out by patients. FSSG is a use-
ful questionnaire for objective assessment of the therapeu-
tic response of GERD (25). This questionnaire included
twelve questions with five dysmotility-like (DS) symptoms
(DS questions about flatulence, feeling heavy or sick af-
ter meals, feeling full while eating meals, as well as much
burping) and seven acid reflux-related symptoms (RS ques-
tions about heartburn, regurgitation into the throat, chest
rubbing, heartburn after meals or while bending, burning
sensation in throat, and difficulty swallowing). The utmost
scores of total FSSG, DS, and RS were 48, 20, and 28, respec-
tively. Also, with this questionnaire, patients had no diffi-
culty in rating their symptoms as occurring occasionally
(about 30% of the time), sometimes (50%), often (70%), or
always (100%) (25, 26). At the end of the intervention, the
same questionnaire was completed by patients. In addi-
tion, the efficacy of each treatment was assessed by sub-
jects using the visual analogue scale (27). VAS scores were
compared within each group and between the two groups
before and 4 weeks after the intervention.
2.4. Randomization
Fifty-eight eligible patients were randomized into two
parallel groups. Then, the patients were randomly as-
signed to one of the groups with simple block randomiza-
tion method that was carried out by applying NCSS (statis-
tical software). Only statisticians were blind to the alloca-
tion of the patients.
2.5. Preparation of Plant Material
S. hortensis was collected from Varamin, Iran, in 2015
and identified by a botanist (whose name is Mohammad
Kamalinejad) at Shahid Beheshti University of Medical Sci-
ences. S. hortensisplants were dried in indirect light at 25°C
in the room, and the whole dried plants were powdered by
micronized steel mill and passed through a 32 mesh-sized
sieve. The powders were packaged in 500 mg capsules, and
placebo capsules were filled with cornstarch in accurately
2 Iran Red Crescent Med J. In Press(In Press):e57953.
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same-looking capsules as used for the S. hortensisgroup. Sa-
vory is an edible vegetable for which the usage dose has
been mentioned 1 to 4 g daily (28); in this study, savory cap-
sules were administered at a dosage of 500 mg three times
a day (equivalent to 1.5 g). S. hortensismedications were pre-
pared in gelatin capsule form.
2.6. Intervention
When the diagnosis of GERD was confirmed by a gas-
troenterologist, the patients were divided into two groups.
Patients were randomly assigned to receive either a four-
week capsule of “S. hortensis” three times per day before
meals for a period of four weeks as the intervention group,
or placebo capsule with the same method as the control
group. Participants in both groups received lifestyle modi-
fication commands by a written form during the study pe-
riod. Items of lifestyle modification form were: avoid eat-
ing at least 3 hours prior bedtime and elevate the head of
the bed, eat a light meal for dinner and avoid fries, chili or
salty foods, avoid tobacco, chocolate, caffeine or coffee, cit-
rus, mint or spicy food, avoid drinking water and beverage
between meals and at least two hours thereafter, chew your
food morsel well until it is almost a liquid.
Then, a standardized questionnaire of frequency scale
for the symptoms of GERD (FSSG) was filled out by patients
before and after the intervention (25, 26). In addition, the
efficacy of each treatment was assessed by subjects using
the visual analogue scale (27).
2.7. Ethical Issues
The study protocol was according to the declaration
of Helsinki (Hong Kong revisions, 1983), approved by the
ethics committee of Iran University of Medical Sciences,
and registered in the Iranian registry of clinical trials
(IRCT2015072215860N2).
2.8. Statistical Analysis
Data are shown as mean + standard deviation and were
analyzed using SPSS Version 16. A significance level equal
to or greater than 0.05 was considered. The changes in
FSSG parameters score before and after the intervention
in each group and between the two groups were statisti-
cally analyzed by paired samples test, Chi-square, and inde-
pendent T-test. In addition, Mann-Whitney U test and sign
test were used for independent and dependent samples, re-
spectively.
3. Results
A total of 58 patients were enrolled as subjects in this
study. The mean age was 38.29 ± 13.29 in the S. hortensis
group and 36.06 ± 9.24 in the placebo group. There was
no significant difference between the two groups in terms
of demographic characteristics (Table 1). In addition, no
significant difference was seen in the FSSG total score, DS,
RS, VAS, flatulence, and burp baseline scores between the
two groups. Figure 1 is a flow diagram of the enrollment,
groups’ allocation, interventions, follow-up, and the anal-
ysis of the results. In both groups, FSSG total score, DS, RS,
VAS, flatulence, and burp scores decreased significantly in
comparison with the respective baselines (Table 2), but at
the end of the study, the comparison of the two groups re-
vealed no significant difference in any of the investigated
options.
4. Discussion
The results of this study indicate that the scores of FSSG
total, DS, and RS, VAS, flatulence, and burp significantly de-
creased in comparison with the respective baselines; that
is, dysmotility-like symptoms, as well as acid reflux-related
symptoms, were better than before the study. Esophageal
motility disturbances and esophageal clearance reduc-
tion, respectively, are shown as pathological mechanisms
of GERD (29). Esophageal dysmotility can be an additive
factor which leads to an increase in the esophageal acid
contact time and increases the severity of reflux disease
from non-erosive to erosive reflux disease, also, causing
chronic mucosal inflammation and impaired esophageal
acid clearance (30-32).
S. hortensis has a historical background in folklore
medicine as a food spice, gastro tonic, and antiseptic (21,
33). Several known effects have been discovered for S. hort-
ensis in vitro and in vivo studies, such as antinociceptive,
antimicrobial, antifungal, and anti-inflammatory activi-
ties as well as a cholesterol-lowering effect (22, 29, 34).
This study is the first clinical trial that investigated the
effectiveness of S. hortensis in patients with GERD, to the
best of our knowledge. In spite of the fact that there were
several studies on the efficacy of S. hortensis and its deriva-
tives, especially carvacrol, in many diverse conditions as an
antimicrobial, antifungal, antitumor, analgesic, antispas-
modic, and anti-inflammatory agent, there was no infor-
mation about its role in GERD.
In this study, the improvement of dysmotility-like
symptoms may be due to carvacrol as a major component
of S. hortensis. Many useful effects of carvacrol on gas-
trointestinal ailments found in this study are consistent
with other studies (21-24). Furthermore, the beneficial ef-
fects (anti-inflammatory antibacterial, antiviral, antifun-
gal, anti-oxidant, and pain relieving) of S. hortensis might
affect heartburn and pain as symptoms of GERD, a fact that
Iran Red Crescent Med J. In Press(In Press):e57953. 3
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Patients with typical 
symptoms of GERD
(n = 80)
Excluded (n = 22)
Not meeting inclusion criteria (n = 8)
Declined to participate (n = 14)
Analyzed (n = 18)
Placebo
+
Life style
 (n = 31)
Allocation
Follow up
Lost to follow up (n = 2)
Discontinued life style (n = 2)
Discontinued placebo 
capsules (n = 6)
Lost to follow up (n = 1)
Discontinued life style (n = 4)
Discontinued S. hortensis 
capsules (n = 4)
Randomized (n = 58)
S. hortensis
+
Life style 
(n = 27)
Analyzed (n = 21)
Figure 1. CONSORT (Consolidated Standards of Reporting Trials) Flow Diagram
Table 1. Demographic Data of the Patientsa
Variable Satureja (N = 21) Placebo (N = 18) P Value
Age, y 38.29± 13.29 36.06± 9.24 0.117
Male/female 12/9 11/7 0.346
Duration of illness, mo 30.04± 40.28 37.36± 45.36 0.778
Marital Status: Single/Married 5/10 5/11 0.197
aValues are expressed as mean± SD or number.
could be related to its anti-inflammatory effect on the mu-
cosa of the esophagus and its pain relief (21-23). Overall, our
results showed that some of the pathological mechanisms
of GERD can be affected by S. hortensis, as well as flatulence
4 Iran Red Crescent Med J. In Press(In Press):e57953.
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Table 2. Pre- and Post-Treatment DS, RS, FSSG, VAS, Flatulence, and Burp Total Scores
Variables Groups P Value
S. hortensis Plplacebo
DS (Dysmotility-like symptoms)
Before 10.33±4.98 9.83±5.13 0.760
After 6.09±4.72 5.66±4.02 0.764
P value 0.000 0.000
RS (acid reflux- related symptoms)
Before 7.90±5.93 8.27± 5.80 0.844
After 4.04± 3.52 4.22± 4.37 0.891
P value 0.000 0.000
FSSG (questionnaire of frequency scale for the symptoms of GERD)
Before 18.83± 8.41 18.23± 8.63 0.829
After 10.11± 6.69 10.14± 7.05 0.989
P value 0.000 0.000
VAS (visual analogue scale)
Before 6.43±1.85 6.11±1.56 0.214
After 3.57±1.53 3.89±1.87 0.239
P value 0.001 0.001
Flatulence
Before 2.62± 1.24 2.50± 1.46 0.785
After 1.48± 1.16 1.56± 1.09 0.829
P value 0.001 0.001
Belching
Before 2.43± 1.16 1.67± 1.15 0.349
After 2.00± 1.64 1.17± 1.38 0.226
P value 0.006 0.005
and burp that significantly decreased compared to the re-
spective baselines. Seemingly, S. hortensis can be useful in
dyspepsia; however, further studies should be done to con-
firm this suggestion.
The results of the current study showed that in
groups, S. hortensis and placebo, GERD symptoms im-
proved, though we expected improvements in the S. hort-
ensis group to be more than those in the placebo group.
However, the comparison of these two groups showed no
significant differences in the improvement of GERD symp-
toms. Thus, it would be better to conduct a study with an-
other group to evaluate only the effect of lifestyle without
taking placebo; this was one of the limitations of our study.
It seems that one of the main reasons for this outcome is
lifestyle modification in both groups based on previous
studies (35, 36). Moreover, the small sample of the study
could be another reason; also, it might be because of phar-
maceutical dosage forms of S. hortensis capsules. Since the
pharmaceutical form used in this study was powdered S.
hortensis, it is possible the rates of carvacrol and other main
components of the aerial parts were probably less than in
syrup or other pharmaceutical forms. In addition, the ap-
plied dose of S. hortensis is mentioned to be 1 to 4 g daily
(28); in this study, S. hortensis capsules were administered
at a dosage of 500 mg three times daily (equivalent to 1.5
g), so it is likely that if the intervention was done with a
higher dose of S. hortensis, or in the syrup form, the results
between the two groups (S. hortensis and placebo) would
be significantly different.
4.1. Study Limitations
Our study had some limitations. The small sample size
of the study should be considered as a major limitation.
It is probable that if the study sample size was higher, we
Iran Red Crescent Med J. In Press(In Press):e57953. 5
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would obtain better results from the study. The functional
status of the participant was measured by the FSSG ques-
tionnaire, as a reliable and valid tool. Therefore, another
important limitation was the absence of objective mea-
sures for assessment of participants’ functionality. In ad-
dition, this study was faced with another constraint: open-
label studies may have some bias. Possibly, we could opine
better about the effectiveness S. hortensis in GERD if we had
a third group that received only placebo capsule without
lifestyle modification. Finally, the lack of dose adjustment
or multiple dose evaluation of S. hortensis in the present
trial is yet one more problem, which should be considered
in oncoming trials.
4.2. Conclusion
According to the results of the current study, Satureja
hortensis L. with a dose of 500 mg three times per day failed
to improve the symptoms of GERD in adults compared to
placebo. The significant reductions in GERD scores in both
groups seem to be related to lifestyle modification that was
prescribed to both groups.
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